title: Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
abstract: Nonmyeloablative conditioning is less toxic and results in initial establishment of mixed hematopoietic T cell chimerism for up to half a year with prolonged presence of host T cell immunity. In this study, we examined whether this translates into differences in the risks and/or severity of cytomegalovirus (CMV) infection and disease. We analyzed data from 537 nonmyeloablative (NM-HCT) and contemporaneous 2489 myeloablative hematopoietic cell transplant (M-HCT) recipients. In CMV seropositive recipients, no difference in the overall hazards of CMV infection at any level (adjusted hazard ratio [adj. HR] 0.9, 95% confidence interval [95% CI]: 0.7-1.0, P = .14) was noted; however, NM-HCT was associated with a lower risk of high-grade CMV infection (adj. HR 0.7, 95% CI: 0.5-0.9, P = .02). CMV disease rates were similar between the groups during the first 100 days after HCT, but NM-HCT recipients had an increased risk of late CMV disease (adj. HR 2.0, 95% CI 1.2-3.4). The increased risk of late CMV disease after NM-HCT was pronounced during the earlier years of the study period, but not detectable in more recent years. Contrary to earlier reports, survival following CMV disease was not reduced after NM-HCT when compared to M-HCT recipients. These results suggest that residual host cells after NM-HCT reduce progression to higher CMV viral load in NM-HCT recipients; however, this effect does not appear to protect against serious complications of CMV. Therefore, CMV prevention strategies in NM-HCT recipients should be similar to those used in M-HCT recipients.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Nakamae
authors.forename: Katharine A
authors.initials: KA
authors.lastname: Kirby
authors.forename: Brenda M
authors.initials: BM
authors.lastname: Sandmaier
authors.forename: Lalita
authors.initials: L
authors.lastname: Norasetthada
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney
authors.forename: Michael B
authors.initials: MB
authors.lastname: Maris
authors.forename: Chris
authors.initials: C
authors.lastname: Davis
authors.forename: Lawrence
authors.initials: L
authors.lastname: Corey
authors.forename: Rainer
authors.initials: R
authors.lastname: Storb
authors.forename: Michael
authors.initials: M
authors.lastname: Boeckh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control / Q000635:transmission; D004198:Disease Susceptibility; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007156:Immunologic Memory; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D007223:Infant; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000453:epidemiology; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D011183:Postoperative Complications / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D012189:Retrospective Studies; D012306:Risk; D016176:T-Lymphocyte Subsets / Q000276:immunology; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous / Q000009:adverse effects; D014766:Viremia / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D014916:Whole-Body Irradiation / Q000009:adverse effects*; D055815:Young Adult
chemical_list: D000890:Anti-Infective Agents; D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists